Shape Pharmaceuticals Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$13M
Shape Pharmaceuticals General Information
Description
Developer of suberohydroxamic acid phenyl ester. The company develops topical histone deacetylase inhibitor SHP-141 for the treatment of cutaneous T-Cell lymphoma.
Contact Information
Website
www.shapepharma.comCorporate Office
- 55 Cambridge Parkway
- Suite 301
- Cambridge, MA 02142
- United States
Corporate Office
- 55 Cambridge Parkway
- Suite 301
- Cambridge, MA 02142
- United States
Shape Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 07-Apr-2014 | $13M | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series B) | 07-Oct-2010 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 07-Oct-2010 | $2M | $2M | Completed | Generating Revenue | |
| 1. Grant | 27-Jul-2010 | $3.3M | Completed | Clinical Trials - Phase 1 |
Shape Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Shape Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Shape Pharmaceuticals Patents
Shape Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2012051416-A1 | Pharmaceutical formulation for histone deacetylase inhibitors | Inactive | 13-Oct-2010 |
Shape Pharmaceuticals Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| HealthCare Ventures | Venture Capital | Minority | ||
| Therapy Acceleration Program (TAP) | Not-For-Profit Venture Capital |
Shape Pharmaceuticals FAQs
-
When was Shape Pharmaceuticals founded?
Shape Pharmaceuticals was founded in 2008.
-
Where is Shape Pharmaceuticals headquartered?
Shape Pharmaceuticals is headquartered in Cambridge, MA.
-
What industry is Shape Pharmaceuticals in?
Shape Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Shape Pharmaceuticals a private or public company?
Shape Pharmaceuticals is a Private company.
-
What is the current valuation of Shape Pharmaceuticals?
The current valuation of Shape Pharmaceuticals is .
-
What is Shape Pharmaceuticals’s current revenue?
The current revenue for Shape Pharmaceuticals is .
-
How much funding has Shape Pharmaceuticals raised over time?
Shape Pharmaceuticals has raised $3M.
-
Who are Shape Pharmaceuticals’s investors?
HealthCare Ventures and Therapy Acceleration Program (TAP) have invested in Shape Pharmaceuticals.
-
When was Shape Pharmaceuticals acquired?
Shape Pharmaceuticals was acquired on 07-Apr-2014.
-
Who acquired Shape Pharmaceuticals?
Shape Pharmaceuticals was acquired by TetraLogic Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
